

CITATION REPORT

List of articles citing

Review article: Infliximab therapy for inflammatory bowel disease--seven years on

DOI: 10.1111/j.1365-2036.2006.02786.x

Alimentary Pharmacology and Therapeutics, 2006, 23, 451-63

Source: <https://exaly.com/paper-pdf/40425737/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
212	Infliximab in ulcerative colitis. 2006 , 35, 821-36		13
211	Le point sur les anticorps autorisés en imagerie et en immunothérapie. 2006 , 21, 255-263		
210	Quality of life after proctocolectomy with ileoanal anastomosis for patients with ulcerative colitis. 2006 , 40, 669-77		67
209	Bibliography. Current world literature. Inflammatory bowel disease. 2006 , 22, 448-67		
208	Bibliography. Current world literature. Stomach and duodenum. 2006 , 22, 680-9		
207	Systematic review: Infliximab therapy in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 25, 19-37	6.1	100
206	Cardiac involvement in children with IBD during infliximab therapy. 2006 , 12, 828-9		5
205	Reactive hemophagocytic syndrome complicating the treatment of inflammatory bowel disease. 2006 , 12, 573-80		34
204	Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. 2006 , 56, 226-43		169
203	Drug therapy of inflammatory bowel disease in fertile women. 2006 , 101, S633-9		8
202	Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. 2008 , 57, 549-58		134
201	Are we ready for top-down therapy for inflammatory bowel diseases: con. 2007 , 1, 249-55		1
200	Treatment with biologic therapies and the risk of cancer in patients with IBD. 2007 , 4, 78-91		35
199	Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?. 2007 , 56, 1181-3		38
198	Chronisch-entzündliche Darmerkrankungen - Konservative und postoperative Therapie. 2007 , 42, 359-365		
197	[Crohn's disease--infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-alpha treatment]. 2007 , 132, 1770-4		7
196	Treatment of Crohn's disease with certolizumab pegol. 2007 , 3, 683-94		3

195	Fibrogenesis in Crohn's disease. 2007 , 102, 439-48	213
194	Maintenance of medically induced remission of Crohn's disease. 2007 , 76, 116-29	3
193	Re-induction as a possible alternative modality of dose escalation of infliximab: a prospective evaluation in a small series of psoriatic patients. 2007 , 20, 647-50	15
192	Current World Literature. 2007 , 23, 199-215	
191	The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease. 2007 , 19, 789-94	33
190	Inflammatory bowel diseases: current treatment strategies and potential for drug delivery using artificial cell microcapsules. 2007 , 454-468	1
189	[Infliximab therapy for inflammatory bowel disease: seven years on]. 2007 , 67, 344-51	1
188	Anti-tumor necrosis factor therapies for psoriasis. 2007 , 2, 335-349	4
187	Infliximab therapy for pediatric Crohn's disease. <i>Expert Opinion on Biological Therapy</i> , 2007 , 7, 1869-80	5.4 11
186	The role of anti-tumor necrosis factor-alpha therapy in Pyoderma gangrenosum associated with inflammatory bowel disease. 2007 , 8, 67-77	30
185	Quantitative gene expression of cytokines in peripheral blood leukocytes stimulated in vitro: modulation by the anti-tumor necrosis factor-alpha antibody infliximab and comparison with the mucosal cytokine expression in patients with ulcerative colitis. 2007 , 150, 223-32	16
184	[Common errors in the management of the seriously ill patient with inflammatory bowel disease]. 2007 , 30, 294-314	0
183	[Current status of inflammatory bowel disease treatment]. 2007 , 207, 298-300	0
182	[Infliximab therapy in ulcerative colitis: initial experience in two referral centers]. 2007 , 30, 449-53	2
181	Infliximab therapy in children and adolescents with inflammatory bowel disease. 2007 , 67, 1703-23	30
180	Infliximab in paediatric inflammatory bowel disease. 2007 , 1, 2-9	7
179	Infliximab in Crohn's disease: TREAT your friend as if he might become an enemy?. 2007 , 13, 933-4	1
178	Drug therapy for inflammatory bowel disease in pregnancy and the puerperium. 2007 , 21, 835-47	23

177	The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. 2007 , 151, 915-29		429
176	Management of inflammatory bowel disease in adults. 2007 , 8, 65-71		22
175	Review article: Reproduction in the patient with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 26, 513-33	6.1	78
174	Resource use in patients with Crohn's disease treated with infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , 2007 , 26, 1313-23	6.1	32
173	Review article: the evidence base for interventions used to maintain remission in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 27, 11-8	6.1	33
172	Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 27, 19-30	6.1	77
171	Modulation by heme and zinc protoporphyrin of colonic heme oxygenase-1 and experimental inflammatory bowel disease in the rat. 2007 , 561, 164-71		33
170	Biologische Therapie chronisch entzündlicher Darmerkrankungen. 2007 , 155, 118-126		
169	Alleviation of experimental ulcerative colitis with the synthetic peptide, F2A4-K-NS (Fibratide). 2007 , 52, 2054-62		5
168	Future therapy for inflammatory bowel disease: should we rethink what we mean by "top down"? <i>Current Gastroenterology Reports</i> , 2007 , 9, 355-7	5	
167	Biologic therapy for inflammatory bowel disease comes of age. <i>Current Gastroenterology Reports</i> , 2007 , 9, 485-488	5	3
166	Alternative strategies for the use of infliximab in pediatric inflammatory bowel disease. <i>Current Gastroenterology Reports</i> , 2008 , 10, 302-7	5	2
165	Quality of life of patients with ulcerative colitis: past, present, and future. 2008 , 14, 554-65		96
164	Everolimus for refractory Crohn's disease: a case report. 2008 , 14, 874-7		26
163	Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use. 2008 , 14, 1168-70		18
162	Global rates of Crohn's disease. 2008 , 14, 1170-2		3
161	Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn's disease. 2008 , 14, 1197-204		29
160	Patterns of infliximab use among Crohn's disease patients in a community setting. 2008 , 14, 1265-72		8

159	Mucosal macrophages and the regulation of immune responses in the intestine. 2008 , 119, 22-31	86
158	Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study. 2008 , 41, 960-7	51
157	Use of combination therapy in IBD. 2008 , 14 Suppl 2, S219-21	1
156	Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase. 2008 , 153, 983-91	37
155	[Practical use of anti-TNF monoclonal antibodies in inflammatory bowel diseases]. 2008 , 32, 467-77	
154	Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response. 2008 , 31, 421-6	21
153	Infliximab in Crohn's disease: early and long-term treatment. 2008 , 40 Suppl 2, S271-9	12
152	Current treatment of inflammatory bowel disease in children. 2008 , 40, 16-21	12
151	Recent advances in the management of Crohn's disease. 2008 , 40, 709-16	10
150	Regulation of the eicosanoid pathway by tumour necrosis factor alpha and leukotriene D4 in intestinal epithelial cells. 2008 , 79, 223-31	15
149	[Efficacy of premedication with intravenous corticosteroids and antihistaminics in preventing infusion reactions to infliximab]. 2008 , 31, 629-32	6
148	Crohn's disease: current treatment options. 2008 , 93, 787-92	32
147	[Perianal fistulas in Crohn's disease--biologicals and surgery: is it worthwhile?]. 2008 , 46, 1376-83	2
146	[Benefits and risks of immunosuppression in chronic inflammatory bowel diseases]. 2008 , 133, 1917-21	0
145	Biologics in asthma: difficulties and drawbacks. <i>Expert Opinion on Biological Therapy</i> , 2008 , 8, 1921-8	5.4 7
144	Use of combination therapy in IBD. 2008 , 14, S219-S221	0
143	Safety and efficacy of adalimumab in pediatric patients with Crohn disease. 2008 , 47, 19-25	39
142	Irritable bowel syndrome--the new inflammatory bowel disease?. 2008 , 8, 417-9	5

141 Gastroenterology. **2008**, 8, 414-7

140 How expensive is inflammatory bowel disease? A critical analysis. *World Journal of Gastroenterology*, **2008**, 14, 6641-7

5.6 52

139 Treatment of inflammatory bowel disease: a review of medical therapy. *World Journal of Gastroenterology*, **2008**, 14, 354-77

5.6 163

138 Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease. **2009**, 104, 760-767

137 Infliximab: A Review of its Use in the Treatment of Crohn's Disease. **2009**, 1, CMT.S2250

136 Análise de custo-minimização entre o Infliximabe (IFX) e o Adalimumabe (ADA) no tratamento da doença de Crohn (DC). **2009**, 29, 158-168

5

135 Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. **2009**, 23, 185-202

33

134 Serum sickness-like reaction associated with efalizumab. **2009**, 43, 383-6

15

133 Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. **2009**, 15, 1264-75

98

132 Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort. **2009**, 23, 277-82

36

131 Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos. **2009**, 100, 386-413

61

130 European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. **2009**, 3, 47-91

393

129 Spanish Evidence-Based Guidelines on the Treatment of Moderate to Severe Psoriasis with Biologic Agents. **2009**, 100, 386-413

1

128 Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. **2009**, 44, 727-35

46

127 Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. **2009**, 104, 760-7

486

126 Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease. **2009**, 43, 950-6

18

125 Use of biologic agents in pediatric inflammatory bowel disease. **2009**, 21, 646-50

1

124 Symposium on 'The challenge of translating nutrition research into public health nutrition'. Session 3: Joint Nutrition Society and Irish Nutrition and Dietetic Institute Symposium on 'Nutrition and autoimmune disease'. Nutrition in Crohn's disease. **2009**, 68, 127-34

16

123 Engineering Of Therapeutic Proteins. **2009**,

122 Infliximab in the treatment of pediatric Crohn's disease. **2009**, 6, 15-22

2

121 Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies?. **2009**, 48, 257-67

31

120 Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update. **2010**, 22, 779-86

11

119 How to manage the infectious risk under anti-TNF in inflammatory bowel disease. **2010**, 11, 198-218

14

118 Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease. **2010**, 50 Suppl 1, S14-34

39

117 Abdominal sonographic changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's Disease. **2010**, 55, 404-10

52

116 Adalimumab treatment in children with refractory Crohn's disease. **2010**, 55, 747-53

32

115 Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab. **2010**, 55, 1413-20

17

114 Perioperative infliximab application ameliorates acute rejection associated inflammation after intestinal transplantation. **2010**, 10, 2431-41

24

113 Therapeutic hotline: Re-induction may be useful to manage psoriasis relapse during long-term maintenance treatment with infliximab: a retrospective analysis. **2010**, 23, 199-202

6

112 Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice. *Alimentary Pharmacology and Therapeutics*, **2010**, 31, 553-60

6.1

47

111 Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. *Alimentary Pharmacology and Therapeutics*, **2010**, 32, 384-93

6.1

40

110 [A case of psoriasis induced by infliximab treatment for Crohn's disease]. **2010**, 56, 324-8

5

109 Ineffectiveness of infliximab therapy in severe infantile Crohn's disease. **2010**, 4, 106-9

1

108 A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. **2010**, 4, 221-56

68

107 [Markers of the course of inflammatory bowel disease treated with immunomodulators or biological agents]. **2010**, 33, 449-60

106 Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. **2011**, 45, 113-8

97

105	KSR1 is a functional protein kinase capable of serine autophosphorylation and direct phosphorylation of MEK1. 2011 , 317, 452-63	18
104	Segmental colitis associated with diverticulosis: complication of diverticular disease or autonomous entity?. 2011 , 56, 27-34	72
103	[Intensive care and inflammatory bowel diseases (IBD). The severe and fulminant flare]. 2011 , 52, 833-40	
102	Case report of aseptic meningitis in a patient with Crohn's disease under infliximab therapy. 2011 , 17, E10	9
101	[Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology]. 2011 , 49, 534-42	
100	Cytokine blockade in inflammatory bowel diseases. 2011 , 3, 1341-52	64
99	Acute infusion reactions induced by monoclonal antibody therapy. 2011 , 7, 55-63	82
98	Azathioprine and Infliximab: Monotherapy or Combination Therapy in the Treatment of Crohn's Disease. 2011 , 4, CGast.S5256	1
97	Infliximab in drug-naïve patients with failed ileorectal anastomosis for Crohn's disease: a new chance for sparing the rectum?. 2011 , 46, 163-8	19
96	Trial discontinuation: lessons for future trial design?. 2012 , 2, 147-152	
95	Methotrexate in inflammatory bowel disease: a multicenter retrospective study focused on long-term efficacy and safety. The Madrid experience. 2012 , 24, 1086-91	19
94	Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis. 2012 , 24, 1078-85	50
93	Granular cell tumour in a patient with Crohn's disease treated with infliximab: coincidence or causal relationship?. 2012 , 24, 857-9	4
92	Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF- α inhibitors. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 36, 858-65	6.1 31
91	An update of the role of nutritional therapy in the management of Crohn's disease. 2012 , 47, 872-82	32
90	Factors associated with the loss of response to infliximab in patients with Crohn's disease. 2012 , 59, 410-6	10
89	Prevention and management of infectious complications in IBD. 2012 , 30, 408-14	17
88	Intensification of infliximab therapy in Crohn's disease: efficacy and safety. 2012 , 6, 62-7	32

87	Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. 2012 , 18, 2034-42	50
86	Pre-operative use of anti-TNF- α agents and the risk of post-operative complications in patients with ulcerative colitis - a nationwide cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 1301-9 ^{6.1}	61
85	Simvastatin attenuates intestinal fibrosis independent of the anti-inflammatory effect by promoting fibroblast/myofibroblast apoptosis in the regeneration/healing process from TNBS-induced colitis. 2012 , 57, 335-44	32
84	Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab. 2013 , 3, 1-14	5
83	Comparative analysis of adverse events between infliximab and adalimumab in Crohn's disease management: a Brazilian single-centre experience. 2013 , 33, 033-038	1
82	Molecular Genetics of Inflammatory Bowel Disease. 2013 ,	
81	[Multiple sclerosis as an adverse effect of anti-tumor necrosis factor agents: an infrequent but important complication of infliximab in Crohn's disease]. 2013 , 36, 81-5	2
80	Pre-operative use of anti-TNF- α agents and the risk of post-operative complications in patients with Crohn's disease--a nationwide cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 214-24 ^{6.1}	67
79	Combined modality treatment for complex fistulating perianal Crohn's disease. 2013 , 15, 210-6	31
78	Death-associated protein kinase controls STAT3 activity in intestinal epithelial cells. 2013 , 182, 1005-20	22
77	Interferon- γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis. 2013 , 169, 1133-40	20
76	Biologic fatigue in psoriasis. 2014 , 25, 78-82	49
75	Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. 2014 , 13, 1699-708	25
74	Utilization trends of anti-TNF agents and health outcomes in adults and children with inflammatory bowel diseases: a single-center experience. 2014 , 20, 1242-9	33
73	Drug delivery strategies in the therapy of inflammatory bowel disease. 2014 , 71, 58-76	149
72	Long-term durability and dose escalation patterns in infliximab therapy for psoriasis. 2014 , 70, 525-32	24
71	Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. 2014 , 1-10	1
70	Targeting sirtuin-1 alleviates experimental autoimmune colitis by induction of Foxp3+ T-regulatory cells. 2014 , 7, 1209-20	48

69	▮ Nicotinic Acetylcholine Receptor is a Novel Mediator of Sinomenine Anti-Inflammation Effect in Macrophages Stimulated by Lipopolysaccharide. 2015 , 44, 188-95		31
68	New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 972-9	6.1	41
67	New Insights into the Mechanisms of Action of Anti-Tumor Necrosis Factor- α Monoclonal Antibodies in Inflammatory Bowel Disease. 2015 , 21, 2909-20		32
66	Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial. 2015 , 21, 2114-22		31
65	Economic implications of biological therapy for Crohn's disease. 2015 , 10, 197-202		1
64	Optimal management of steroid-dependent ulcerative colitis. 2015 , 8, 293-302		12
63	A review of the impact of biologics on surgical complications in Crohn's disease. 2015 , 21, 1472-7		16
62	Classical and recent advances in the treatment of inflammatory bowel diseases. 2015 , 48, 96-107		58
61	Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. 2015 , 2015, 493012		106
60	Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. 2015 , 71, 773-99		11
59	Management of IBD Patients with Current Immunosuppressive Therapy and Concurrent Infections. 2015 , 33 Suppl 1, 50-56		7
58	Inflammatory bowel disease of the lung: The role of infliximab?. 2015 , 15, 85-8		12
57	Safety considerations when using anti-TNF α therapy to treat Crohn's disease. 2015 , 14, 31-44		7
56	Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease. 2015 , 50, 758-68		9
55	Adalimumab therapy in children with Crohn disease previously treated with infliximab. 2015 , 60, 205-10		23
54	Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. 2015 , 9 Suppl 1, 45-52		83
53	Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series. 2015 , 60, 951-6		101
52	Antibody-Based Targeted Delivery of Interleukin-22 Promotes Rapid Clinical Recovery in Mice With DSS-Induced Colitis. 2016 , 22, 2098-105		16

51	Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis. 2016 , 51, 1062-8	46
50	A dermatologist guide to immunogenicity. 2016 , 2, 77-84	2
49	Chronic immunosuppression does not potentiate the malignant progression of mucinous pancreatic cystic lesions. 2016 , 16, 900-4	3
48	Clinical efficacy maintains patients' positive attitudes toward fecal microbiota transplantation. 2016 , 95, e4055	19
47	Misdiagnosis and Mistherapy of Crohn's Disease as Intestinal Tuberculosis: Case Report and Literature Review. 2016 , 95, e2436	11
46	Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers. 2016 , 16, 37	27
45	Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. 2016 , 111, 477-91	106
44	Anti-inflammatory effects of physalin E from <i>Physalis angulata</i> on lipopolysaccharide-stimulated RAW 264.7 cells through inhibition of NF- κ B pathway. 2017 , 39, 74-79	19
43	Eldelumab [anti-interferon- γ inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study. 2017 , 11, 811-819	19
42	Epidemiological profile and clinical characteristics of patients with intestinal inflammatory disease. 2017 , 37, 273-278	6
41	Effects of Education and Information on Vaccination Behavior in Patients with Inflammatory Bowel Disease. 2017 , 23, 318-324	20
40	Applications of Genetically Modified Immunobiotics with High Immunoregulatory Capacity for Treatment of Inflammatory Bowel Diseases. 2017 , 8, 22	29
39	Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. 2018 , 24, 2272-2277	7
38	Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment. 2018 , 33, 20-29	8
37	Physalin B Suppresses Inflammatory Response to Lipopolysaccharide in RAW264.7 Cells by Inhibiting NF- κ B Signaling. 2018 , 2018, 1-6	2
36	Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment. 2018 , 16, 4-16	13
35	Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. 2018 , 11, 215-226	71
34	An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease. 2019 , 34, 1633-1652	18

33	Profile of Consecutive Fecal Calprotectin Levels in the Perioperative Period and Its Predictive Capacity for Early Endoscopic Recurrence in Crohn's Disease. 2019 , 62, 318-326		4
32	Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab. 2019 , 31, 187-191		7
31	A Quality Improvement Approach to External Infliximab Infusions in Pediatric Inflammatory Bowel Disease. 2019 , 69, 544-550		1
30	Loss of response to scheduled infliximab therapy for Crohn's disease in adults: A systematic review and meta-analysis. 2019 , 20, 65-72		9
29	Hepatotoxicity of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 Update. <i>Current Gastroenterology Reports</i> , 2020 , 22, 47	5	4
28	The role of colonoscopy in managing diverticular disease of the colon. 2015 , 24, 85-93		17
27	Switching from Reference Infliximab to Biosimilar CT-P13 did not Change Quality of Life in Stable Inflammatory Bowel Disease Patients.		
26	Reindução da remissão clínica com adalimumabe após interrupção do tratamento: uma alternativa no manejo da doença de Crohn. 2010 , 30, 135-140		1
25	Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers. 2019 , 32, 392-399		7
24	Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2009 , 15, 2067-73	5.6	83
23	Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. <i>World Journal of Gastroenterology</i> , 2007 , 13, 5238-44	5.6	42
22	Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness. 2012 , 3, 74-82		8
21	Drug Therapy of Inflammatory Bowel Disease in Fertile Women. 2006 , 101, S633-S639		0
20	State-of-the-Art Lecture: The future of biologic therapy in Asia. 2009 , 70-73		
19	IBD: Medical Management. 2011 , 463-478		
18	Cytokines in Inflammatory Bowel Disease. 2013 , 307-326		
17	Step-Up Versus Top-Down Therapy in Ulcerative Colitis. 2014 , 457-467		
16	Intravitreal Infliximab Injection to Treat Experimental Endophthalmitis. 2017 , 49, 167-171		1

15	Welches Biologikum/Small moleculeIn welcher Situation bei chronisch-entzündlichen Darmerkrankungen?. 2020 , 1, 5-15		
14	Indications for use of infliximab in inflammatory bowel disease. 165-182		
13	Drug focus: adalimumab in the treatment of moderate to severe psoriasis. 2007 , 1, 93-103		12
12	Inflammatory bowel disease of the elderly: a wake-up call. <i>Gastroenterology and Hepatology</i> , 2008 , 4, 337-47	0.7	10
11	Need for infliximab dose intensification in Crohn's disease and ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2014 , 20, 9170-7	5.6	19
10	Colorectal Surgery Review for Primary Care Providers. <i>Missouri Medicine</i> , 2020 , 117, 254-257	0.8	1
9	MRI-Based Radiomic Signature Identifying Secondary Loss of Response to Infliximab in Crohn's Disease.. <i>Frontiers in Nutrition</i> , 2021 , 8, 773040	6.2	
8	Biologic therapy for inflammatory bowel disease comes of age. <i>Current Gastroenterology Reports</i> , 2007 , 9, 485-7	5	
7	Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region.. <i>Alimentary Pharmacology and Therapeutics</i> , 2022 ,	6.1	1
6	Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.. <i>Expert Opinion on Biological Therapy</i> , 2021 , 1-8	5.4	
5	Site-selective oral delivery of therapeutic antibodies to the inflamed colon via a folic acid-grafted organic/inorganic hybrid nanocomposite system. <i>Acta Pharmaceutica Sinica B</i> , 2022 ,	15.5	0
4	Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. <i>BMC Gastroenterology</i> , 2022 , 22,	3	0
3	Histoplasmosis With Diffuse Granulomatous Peritonitis in Crohn's Disease: A Mimic of Peritoneal Carcinomatosis. <i>ACG Case Reports Journal</i> , 2022 , 9, e00766	0.6	
2	The Lactobacillus gasseri G098 Strain Mitigates Symptoms of DSS-Induced Inflammatory Bowel Disease in Mice. 2022 , 14, 3745		1
1	An update on efficacy and safety comparison of biologics in treatment of inflammatory bowel disease targeting TNF- α interleukins, leukocyte trafficking, Janus-kinase, and sphingosine-1-phosphate receptor. 1-25		0